Third Death Reported in China's Opaque CAR-T Trials
TL;DR Summary
A patient with an autoimmune disease died after receiving an experimental CAR-T gene therapy from a Chinese biotech startup, the third fatality in China’s controversial and opaque trials, according to Endpoints News.
Topics:business#autoimmune-disease#car-t-therapy#china-biotech#clinical-trials#patient-safety#science
- Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T Endpoints News
- After 2 undisclosed deaths, can China’s IIT still be trusted? Fierce Biotech
- After 2 Deaths and Reports of Brain Tumors, How Dangerous Is Gene Therapy, Really? Gizmodo
- A fatal reaction Stanford Law School
- Opinion | The Promise and Peril of Gene Editing MedPage Today
Reading Insights
Total Reads
1
Unique Readers
5
Time Saved
0 min
vs 1 min read
Condensed
64%
89 → 32 words
Want the full story? Read the original article
Read on Endpoints News